QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
NASDAQ:AVTX

Avalo Therapeutics (AVTX) Stock Forecast, Price & News

$2.87
-0.16 (-5.28%)
(As of 03:59 PM ET)
Compare
Today's Range
$2.82
$3.01
50-Day Range
$1.61
$3.40
52-Week Range
$1.41
$7.41
Volume
11,729 shs
Average Volume
37,864 shs
Market Capitalization
$37.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50

Avalo Therapeutics MarketRank™ Forecast

Analyst Rating
Reduce
1.00 Rating Score
Upside/​Downside
436.3% Upside
$15.50 Price Target
Short Interest
Healthy
0.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.60mentions of Avalo Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$302,212 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.13) to ($2.13) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

482nd out of 1,009 stocks

Pharmaceutical Preparations Industry

229th out of 494 stocks


AVTX stock logo

About Avalo Therapeutics (NASDAQ:AVTX) Stock

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Receive AVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AVTX Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Reviewing Avalo Therapeutics (AVTX) and Its Rivals
See More Headlines
Receive AVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AVTX Company Calendar

Last Earnings
3/02/2022
Today
5/30/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVTX
Fax
N/A
Employees
42
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.50
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+411.6%
Consensus Rating
Reduce
Rating Score (0-4)
1.00
Research Coverage
1 Analysts

Profitability

Net Income
$-41,660,000.00
Net Margins
-170.36%
Pretax Margin
-170.20%

Debt

Sales & Book Value

Annual Sales
$18.05 million
Book Value
($1.16) per share

Miscellaneous

Free Float
7,208,000
Market Cap
$40.00 million
Optionable
Optionable
Beta
1.62

Key Executives

  • Garry Arthur Neil
    Chairman, President & Chief Executive Officer
  • Dino C. Miano
    Senior Vice President-CMC & Technical Operations
  • Christopher SullivanChristopher Sullivan
    Chief Financial Officer
  • Lisa Hegg
    Senior VP-Infrastructure & Clinical Operation
  • Colleen Matkowski
    SVP-Global Regulatory Affairs & Quality Assurance













AVTX Stock - Frequently Asked Questions

Should I buy or sell Avalo Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avalo Therapeutics in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" AVTX shares.
View AVTX analyst ratings
or view top-rated stocks.

What is Avalo Therapeutics' stock price forecast for 2023?

1 analysts have issued 12 month target prices for Avalo Therapeutics' stock. Their AVTX share price forecasts range from $10.00 to $21.00. On average, they anticipate the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 411.6% from the stock's current price.
View analysts price targets for AVTX
or view top-rated stocks among Wall Street analysts.

How have AVTX shares performed in 2023?

Avalo Therapeutics' stock was trading at $5.0401 at the beginning of the year. Since then, AVTX stock has decreased by 39.9% and is now trading at $3.03.
View the best growth stocks for 2023 here
.

Are investors shorting Avalo Therapeutics?

Avalo Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 43,800 shares, an increase of 17.1% from the April 30th total of 37,400 shares. Based on an average daily trading volume, of 48,000 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.4% of the shares of the company are sold short.
View Avalo Therapeutics' Short Interest
.

When is Avalo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our AVTX earnings forecast
.

How were Avalo Therapeutics' earnings last quarter?

Avalo Therapeutics, Inc. (NASDAQ:AVTX) announced its quarterly earnings data on Wednesday, March, 2nd. The company reported ($1.92) earnings per share for the quarter, missing the consensus estimate of ($1.80) by $0.12. Avalo Therapeutics had a negative trailing twelve-month return on equity of 950.78% and a negative net margin of 170.36%.

When did Avalo Therapeutics' stock split?

Avalo Therapeutics's stock reverse split on Friday, July 8th 2022. The 1-12 reverse split was announced on Friday, July 8th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 8th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Avalo Therapeutics' stock symbol?

Avalo Therapeutics trades on the NASDAQ under the ticker symbol "AVTX."

Who are Avalo Therapeutics' major shareholders?

Avalo Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (33.44%), Great Point Partners LLC (3.60%), Alyeska Investment Group L.P. (3.03%), Braidwell LP (1.87%) and Monashee Investment Management LLC (0.45%). Insiders that own company stock include Armistice Capital, Llc, Caissa Capital Management Ltd, Christopher Ryan Sullivan, Garry Arthur Neil, H Jeffrey Wilkins and Schond L Greenway.
View institutional ownership trends
.

How do I buy shares of Avalo Therapeutics?

Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avalo Therapeutics' stock price today?

One share of AVTX stock can currently be purchased for approximately $3.03.

How much money does Avalo Therapeutics make?

Avalo Therapeutics (NASDAQ:AVTX) has a market capitalization of $40.00 million and generates $18.05 million in revenue each year. The company earns $-41,660,000.00 in net income (profit) each year or ($2.93) on an earnings per share basis.

How can I contact Avalo Therapeutics?

Avalo Therapeutics' mailing address is 540 Gaither Rd Ste 400, Rockville, Maryland 20850-6713. The official website for the company is www.avalotx.com. The company can be reached via phone at (410) 522-8707 or via email at ir@cerecor.com.

This page (NASDAQ:AVTX) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -